Aardvark Competitors
| AARD Stock | 12.91 0.39 2.93% |
Aardvark Therapeutics vs Pyxis Oncology Correlation
Excellent diversification
The correlation between Aardvark Therapeutics Common and PYXS is -0.68 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aardvark Therapeutics Common and PYXS in the same portfolio, assuming nothing else is changed.
Moving together with Aardvark Stock
| 0.78 | EVOK | Evoke Pharma | PairCorr |
| 0.68 | EYPT | Eyepoint Pharmaceuticals | PairCorr |
| 0.84 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.62 | GSK | GlaxoSmithKline PLC ADR Earnings Call Tomorrow | PairCorr |
| 0.65 | JNJ | Johnson Johnson | PairCorr |
Moving against Aardvark Stock
| 0.74 | SNY | Sanofi ADR | PairCorr |
| 0.68 | PIFMY | Indofood Sukses Makmur | PairCorr |
| 0.48 | KALA | Kala Pharmaceuticals | PairCorr |
| 0.47 | PTAIF | PT Astra International | PairCorr |
Aardvark Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aardvark Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Aardvark and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aardvark Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Aardvark Stock performing well and Aardvark Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aardvark Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ASMB | 2.67 | (0.23) | 0.00 | (0.17) | 0.00 | 5.85 | 18.53 | |||
| ZURA | 3.91 | 0.71 | 0.13 | 4.70 | 4.57 | 9.32 | 33.15 | |||
| NAUT | 5.01 | 0.80 | 0.12 | (1.11) | 4.82 | 9.93 | 53.15 | |||
| EPRX | 3.11 | 0.55 | 0.17 | 0.50 | 2.95 | 6.98 | 24.61 | |||
| CRBU | 3.11 | (0.86) | 0.00 | (0.23) | 0.00 | 6.86 | 20.16 | |||
| ENTA | 2.47 | 0.38 | 0.12 | 1.61 | 2.65 | 5.67 | 15.79 | |||
| TNYA | 5.09 | (0.69) | 0.00 | (0.13) | 0.00 | 11.72 | 51.79 | |||
| AVTX | 3.39 | (0.16) | 0.00 | 0.37 | 0.00 | 6.64 | 23.40 | |||
| FHTX | 4.00 | 0.69 | 0.13 | (0.51) | 4.28 | 9.16 | 31.12 | |||
| PYXS | 6.20 | (0.69) | 0.00 | 1.19 | 0.00 | 17.05 | 70.66 |
Cross Equities Net Income Analysis
Compare Aardvark Therapeutics and related stocks such as Assembly Biosciences, Zura Bio Limited, and Nautilus Biotechnology Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASMB | (8.8 M) | (34.3 M) | (24.8 M) | (19.4 M) | (23.8 M) | (28.5 M) | (44.3 M) | (42.8 M) | (90.8 M) | (97.6 M) | (62.2 M) | (129.9 M) | (92.1 M) | (61.2 M) | (40.2 M) | (36.2 M) | (38 M) |
| ZURA | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | (25.7 M) | (60.4 M) | (52.4 M) | (47.2 M) | (49.5 M) |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | (9.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (63.7 M) | (70.8 M) | (63.7 M) | (60.5 M) |
| EPRX | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (13.2 M) | (7.4 M) | (4 M) | (18 M) | (18.5 M) | (28.2 M) | (36.7 M) | (33 M) | (31.4 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (102.1 M) | (149.1 M) | (134.2 M) | (127.5 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| TNYA | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (38.4 M) | (69.7 M) | (123.7 M) | (124.1 M) | (111.1 M) | (100 M) | (105 M) |
| AVTX | (10.5 M) | (10.5 M) | (10.5 M) | (13 M) | (16.1 M) | (10.5 M) | (16.5 M) | 11.9 M | (40.1 M) | (16.1 M) | (63.5 M) | (84.4 M) | (41.7 M) | (31.5 M) | (35.1 M) | (31.6 M) | (33.2 M) |
| FHTX | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (51.1 M) | (68.8 M) | (101.3 M) | (108.9 M) | (98.4 M) | (86.6 M) | (78 M) | (81.9 M) |
| PYXS | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.8 M) | (76 M) | (118 M) | (73.8 M) | (77.3 M) | (69.6 M) | (73.1 M) |
Aardvark Therapeutics and related stocks such as Assembly Biosciences, Zura Bio Limited, and Nautilus Biotechnology Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Aardvark Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aardvark Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Aardvark Therapeutics Competitive Analysis
The better you understand Aardvark Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aardvark Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aardvark Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Aardvark Therapeutics Competition Performance Charts
Five steps to successful analysis of Aardvark Therapeutics Competition
Aardvark Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aardvark Therapeutics in relation to its competition. Aardvark Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Aardvark Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aardvark Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aardvark Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Aardvark Therapeutics position
In addition to having Aardvark Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Aardvark Therapeutics Correlation with its peers. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Will Pharmaceuticals sector continue expanding? Could Aardvark diversify its offerings? Factors like these will boost the valuation of Aardvark Therapeutics. If investors know Aardvark will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aardvark Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aardvark Therapeutics requires distinguishing between market price and book value, where the latter reflects Aardvark's accounting equity. The concept of intrinsic value—what Aardvark Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aardvark Therapeutics' price substantially above or below its fundamental value.
Understanding that Aardvark Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aardvark Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aardvark Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.